Baqsimi, Glucagon, Gvoke Hypopen, Gvoke Pfs, Ogluo (glucagon) is a protein pharmaceutical. Glucagon was first approved as Baqsimi on 1998-09-11. It is used to treat anaphylaxis, bradycardia, cardiogenic shock, hypoglycemia, and hypotension in the USA. It has been approved in Europe to treat diabetes mellitus. The pharmaceutical is active against glucagon receptor. In addition, it is known to target glucagon-like peptide 2 receptor and glucagon-like peptide 1 receptor. Glucagon's patents are valid until 2039-09-23 (FDA).
|Trade Name||Baqsimi, Ogluo|
|Indication||anaphylaxis, bradycardia, cardiogenic shock, diabetes mellitus, hypoglycemia, hypotension|